360 related articles for article (PubMed ID: 15667232)
21. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis.
Bissonnette R; Ho V; Langley RG
J Cutan Med Surg; 2009; 13 Suppl 2():S67-76. PubMed ID: 19799829
[TBL] [Abstract][Full Text] [Related]
22. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
[TBL] [Abstract][Full Text] [Related]
23. Overview of biologic agents in medicine and dermatology.
Sobell JM
Semin Cutan Med Surg; 2005 Mar; 24(1):2-9. PubMed ID: 15900793
[TBL] [Abstract][Full Text] [Related]
24. A method classifying biologics for formulary decision making.
Broder MS; Reissman D
Manag Care Interface; 2006 Apr; 19(4):30-2. PubMed ID: 16689025
[TBL] [Abstract][Full Text] [Related]
25. Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis.
Zou A; Chen Y; Shi N; Ye Y
Medicine (Baltimore); 2021 Oct; 100(40):e27368. PubMed ID: 34622837
[TBL] [Abstract][Full Text] [Related]
26. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
Saini R; Tutrone WD; Weinberg JM
Curr Pharm Des; 2005; 11(2):273-80. PubMed ID: 15638763
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
28. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
Yang H; Craig D; Epstein D; Bojke L; Light K; Bruce IN; Sculpher M; Woolacott N
Pharmacoeconomics; 2012 Apr; 30(4):257-70. PubMed ID: 22283690
[TBL] [Abstract][Full Text] [Related]
29. Therapy of moderate and severe psoriasis.
Claes C; Kulp W; Greiner W; von der Schulenburg JM; Werfel T
GMS Health Technol Assess; 2006 Apr; 2():Doc07. PubMed ID: 21289958
[TBL] [Abstract][Full Text] [Related]
30. Managed care aspects of psoriasis and psoriatic arthritis.
Evans C
Am J Manag Care; 2016 Jun; 22(8 Suppl):s238-43. PubMed ID: 27356195
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
Lee S; Xie L; Wang Y; Vaidya N; Baser O
J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
[TBL] [Abstract][Full Text] [Related]
32. Use of etanercept in the dermatology setting. A review.
Lebwohl MG
Am J Clin Dermatol; 2005; 6(1):49-59. PubMed ID: 15675890
[TBL] [Abstract][Full Text] [Related]
33. [Which patient is a candidate for treatment with efalizumab and why?].
Puig L
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():51-61. PubMed ID: 18341853
[TBL] [Abstract][Full Text] [Related]
34. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
Langley RG; Gupta AK; Cherman AM; Inniss KA
J Cutan Med Surg; 2007; 11(3):99-122. PubMed ID: 17511926
[TBL] [Abstract][Full Text] [Related]
35. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
Weger W
Br J Pharmacol; 2010 Jun; 160(4):810-20. PubMed ID: 20590580
[TBL] [Abstract][Full Text] [Related]
36. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database.
Howe A; Eyck LT; Dufour R; Shah N; Harrison DJ
J Manag Care Spec Pharm; 2014 Dec; 20(12):1236-44. PubMed ID: 25443517
[TBL] [Abstract][Full Text] [Related]
38. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.
Brezinski EA; Armstrong AW
PLoS One; 2012; 7(4):e33486. PubMed ID: 22509259
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of biologics in psoriasis: a review.
Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
[TBL] [Abstract][Full Text] [Related]
40. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
